Febuxostat in the management of hyperuricemia and chronic gout: a review

References

• AbbottRDBrandFNKannelWB1988Gout and coronary heart disease: the Framingham StudyJ Clin Epidemiol41237423339376
   PubMed Web of Science ®Google Scholar
• BeckerMA1988Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout)Rheum Dis Clin North Am14377943051156
   PubMed Web of Science ®Google Scholar
• BeckerMAKisickiJKhosravanR2004aFebuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteersNucleosides Nucleotides Nucleic Acids231111615571211
   PubMed Web of Science ®Google Scholar
• BeckerMASchumacherHRJrWortmannRL2005aFebuxostat compared with allopurinol in patients with hyperuricemia and goutN Engl J Med35324506116339094
   PubMed Web of Science ®Google Scholar
• BeckerMASchumacherHRJrWortmannRL2006Allopurinol intolerant patients treated with febuxostat for 4 yearsACR/ARHP Annual Scientific Meeting
   Google Scholar
• BeckerMASchumacherHRWortmannRLJr2005bFebuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with goutArthritis Rheum529162315751090
   PubMed Web of Science ®Google Scholar
• BeckerMASchumacherRWortmannR2004bFebuxostat, a novel non-purine selective inhibitor of xanthine oxidase, therapy in allopurinol intolerant patientsArthritis Rheum50803/103
   Google Scholar
• BeckerMASchumacherRWortmannR2004cMagnetic resonance imaging of gouty tophi during treatment with febuxostat, a non-purine selective inhibitor of xanthine oxidaseArthritis Rheum50802/103
   Google Scholar
• BenzieIFChungWTomlinsonB1999Simultaneous measurement of allantoin and urate in plasma: analytical evaluation and potential clinical application in oxidant:antioxidant balance studiesClin Chem45901410352002
   PubMed Web of Science ®Google Scholar
• BruceSP2006Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and goutAnn Pharmacother4021879417132810
   PubMed Web of Science ®Google Scholar
• CHMP2008Committee for medicinal products for human use summary of positive opinion for Adenuric [online] 21 February 2008. URL: http://www.emea.europa.eu/pdfs/human/opinion/Adenuric_8075108en.pdf
   Google Scholar
• ChoiHKCurhanG2007Independent impact of gout on mortality and risk for coronary heart diseaseCirculation11689490017698728
   PubMed Web of Science ®Google Scholar
• ChoiHKMountDBReginatoAM2005Pathogenesis of goutAnn Intern Med14349951616204163
   PubMed Web of Science ®Google Scholar
• EmmersonBT1996The management of goutN Engl J Med334445518552148
   PubMed Web of Science ®Google Scholar
• FalascaGF2006Metabolic diseases: goutClin Dermatol2449850817113968
   PubMed Web of Science ®Google Scholar
• FamAG2002Gout, diet, and the insulin resistance syndromeJ Rheumatol291350512136887
   PubMed Web of Science ®Google Scholar
• GrabowskiBAKhosravanRWuJT2005Effect of hydrochlorothiazide on pharmacokinetics and pharmacodynamics of febuxostatArthritis Rheum52S1034
   Web of Science ®Google Scholar
• HakAEChoiHK2008Lifestyle and goutCurr Opin Rheumatol201798618349748
   PubMed Web of Science ®Google Scholar
• HoriuchiHOtaMKobayashiM1999A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in ratsRes Commun Mol Pathol Pharmacol1043071910741381
   PubMed Web of Science ®Google Scholar
• HoshideSTakahashiYIshikawaT2004PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairmentNucleosides Nucleotides Nucleic Acids231117815571212
   PubMed Web of Science ®Google Scholar
• HungSIChungWHLiouLB2005HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinolProc Natl Acad Sci U S A1024134915743917
   PubMed Web of Science ®Google Scholar
• Ipsen2008Adenuric® (febuxostat) receives marketing authorisation in the European Union Ipsen Press Release 5 May 2008 [online]. URL: http://www.ipsen.com/articles/investorrelations/regulatedinformation/20080505___autorisation_adenuric_eu_10.pdf
   Google Scholar
• IsekiKIkemiyaYInoueT2004Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohortAm J Kidney Dis446425015384015
   PubMed Web of Science ®Google Scholar
• KamataniNFujimoriSHadaT2003Phase II dose-response clinical trial using febuxostat (TMX-67), a novel-type xanthine oxidase/xanthine dehydrogenase inhibitor, for gout and hyperuricemiaArthritis Rheum48S530
   Google Scholar
• KamataniNFujimoriSHadaT2004Febuxostat, a novel non-Purine selective inhibitor of xanthine oxidase, in an allopurinol-controlled phase III clinical trial in Japanese subjects with gout or hyperuricemiaArthritis Rheum50804/103
   Google Scholar
• KhosravanRGrabowskiBAMayerMD2006aThe effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidaseJ Clin Pharmacol468810216397288
   PubMed Web of Science ®Google Scholar
• KhosravanRGrabowskiBAWuJT2006bPharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjectsClin Pharmacokinet458214116884320
   PubMed Web of Science ®Google Scholar
• KhosravanRGrabowskiBWuJT2008aEffect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjectsBr J Clin Pharmacol653556317953718
   PubMed Web of Science ®Google Scholar
• KhosravanRKukulkaMJWuJT2008bThe effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidaseJ Clin Pharmacol4810142418635756
   PubMed Web of Science ®Google Scholar
• KhosravanRMayerMDWuJT2005aEffect of concomitant administration of febuxostat and colchicine on pharmacokinetics of febuxostat and colchicine at steady stateArthritis Rheum52supplS1023
   Google Scholar
• KhosravanRWuJTJoseph-RidgeN2006cPharmacokinetic interactions of concomitant administration of febuxostat and NSAIDsJ Clin Pharmacol468556616855070
   PubMed Web of Science ®Google Scholar
• KhosravanRPErdmanKBVernilletLPP2005bEffect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate, in healthy subjectsClin Pharmacol Ther77P43PI137
   PubMed Web of Science ®Google Scholar
• KimKYRalph SchumacherHHunscheE2003A literature review of the epidemiology and treatment of acute goutClin Ther25159361712860487
   PubMed Web of Science ®Google Scholar
• KomoriyaKHoshideSTakedaK2003Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemiaNucleosides Nucleotides Nucleic Acids2311192215571213
   PubMed Web of Science ®Google Scholar
• KomoriyaKHoshideSTakedaK2004Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemiaNucleosides Nucleotides Nucleic Acids2311192215571213
   PubMed Web of Science ®Google Scholar
• KomoriyaKOsadaYHasegawaM1993Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzeesEur J Pharmacol250455608112406
   PubMed Web of Science ®Google Scholar
• KrishnanEBakerJFFurstDE2006Gout and the risk of acute myocardial infarctionArthritis Rheum5426889616871533
   PubMed Web of Science ®Google Scholar
• Li-YuJClayburneGSieckM2001Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?J Rheumatol285778011296962
   PubMed Web of Science ®Google Scholar
• MayerMDKhosravanRVernilletL2005Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairmentAm J Ther12223415662289
   PubMedGoogle Scholar
• MukoyoshiMNishimuraSHoshideS2008In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibitionXenobiotica3849651018421623
   PubMed Web of Science ®Google Scholar
• OkamotoKEgerBTNishinoT2003An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibitionJ Biol Chem27818485512421831
   PubMed Web of Science ®Google Scholar
• OkamotoKNishinoT2008Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051J Nippon Med Sch752318360072
   PubMedGoogle Scholar
• OsadaYTsuchimotoMFukushimaH1993Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodentsEur J Pharmacol24118388243554
   PubMed Web of Science ®Google Scholar
• RoddyEZhangWDohertyM2007The changing epidemiology of goutNat Clin Pract Rheumatol3443917664951
   PubMedGoogle Scholar
• Sanchez-LozadaLGTapiaEBautista-GarciaP2008aEffects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndromeAm J Physiol Renal Physiol294F710818216151
   PubMed Web of Science ®Google Scholar
• Sanchez-LozadaLGTapiaESotoV2008bEffect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemiaNephron Physiol1086978
   Web of Science ®Google Scholar
• Sanchez-LozadaLGTapiaESotoV2008cTreatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemiaNephrol Dial Transplant2311798518048425
   PubMed Web of Science ®Google Scholar
• SchlesingerN2004Management of acute and chronic gouty arthritis: present state-of-the-artDrugs64239941615481999
   PubMed Web of Science ®Google Scholar
• SchumacherHRJrBeckerMAWortmannRL2006The FOCUS trial 48-month interim analysis: long-term clinical outcomes of treatment with febuxostat in subjects with gout in an ongoing phase 2, open-label extension studyACR/ARHP Annual Scientific Meeting
   Google Scholar
• SchumacherHRBeckerMAJrWortmannRL2005Febuxostat vs allopurinol and placebo in subjects with hyperuricemia and gout: the 28-week APEX studyArthritis Rheum52S680
   Google Scholar
• SchumacherHRJrWortmannRBeckerMA2004A phase 2, long term open-label safety and efficacy study of febuxostat, a novel non-purine, selective inhibitor of xanthine oxidaseArthritis Rheum50800/180
   Google Scholar
• SlotO1994[Hyperuricemia]Ugeskr Laeger15623964018009701
   PubMedGoogle Scholar
• TakanoYHase-AokiKHoriuchiH2005Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenaseLife Sci7618354715698861
   PubMed Web of Science ®Google Scholar
• TengGGNairRSaagKG2006Pathophysiology, clinical presentation and treatment of goutDrugs6615476316956303
   PubMed Web of Science ®Google Scholar
• TomlinsonB2005Febuxostat (Teijin/Ipsen/TAP)Curr Opin Investig Drugs6116878
   PubMedGoogle Scholar
• WortmannRBeckerMASchumacherHRJr2004Gout flare prophylaxis during management of chronic gout with febuxostat, a non-purine selective inhibitor of xanthine oxidaseArthritis Rheum50801/103
   Google Scholar
• WortmannRL2002Gout and hyperuricemiaCurr Opin Rheumatol14281611981327
   PubMed Web of Science ®Google Scholar
• WortmannRL2005Recent advances in the management of gout and hyperuricemiaCurr Opin Rheumatol173192415838244
   PubMed Web of Science ®Google Scholar
• WortmannRLBeckerMASchumacherHRJr2006Effect of febuxostat or allopurinol on the clinical manifestations of gout: reduction in gout flares and tophus size over time in the EXCEL trialACR/ARHP Annual Scientific Meeting
   Google Scholar
• ZhaoLRocheBMWessaleJL2008Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: effects of early versus delayed treatmentLife Sci8249550218215719
   PubMed Web of Science ®Google Scholar